In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...

San Francisco, CA - Measurement of serum amino terminal fragment of prohormone brain-type natriuretic peptide (NT-proBNP) can add useful information to the standard risk assessment of people with ...

Measuring N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels preoperatively among patients scheduled to undergo inpatient noncardiac surgery can strongly predict the risk of major cardiac ...

LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited, a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of care NT-proBNP ...

The diagnostic potential of N-terminal pro-B-type natriuretic peptide (NT-proBNP) testing in patients with suspected heart failure (HF) has been demonstrated, but whether this test reduces costs and ...

NT-proBNP (B-type natriuretic peptide) is a biomarker used widely as an aid in the diagnosis of congestive heart failure and has also been established as a marker for prognosis in Acute Coronary ...

Mumbai: Roche Diagnostics India announces the launch of its point-of-care (PoC) NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure ...

In search of the Point-of-Care NT-proBNP Test in the USA? Reach out to Response Biomedical today for prompt assistance. Contact us now! VANCOUVER, WASHINGTON, USA, May 24, 2023/einpresswire.com / -- ...

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is ...